Tirzepatide Explained: How Mounjaro and Zepbound Work, and Why It’s Called a “Dual Agonist”

Medically reviewed by the UTCardiothoracicSurgery.com editorial team | Published April 3, 2026

Disclaimer: This article is for educational purposes only and doesn't constitute medical advice. GLP-1 medications are prescription drugs that require evaluation by a licensed healthcare provider. Don't start, stop, or change any medication without consulting your doctor.

Tirzepatide: The Dual-Action Medication That's Outperforming Semaglutide

If semaglutide changed the weight loss medication conversation, tirzepatide rewrote it. In head-to-head clinical trials, tirzepatide has consistently produced greater average weight loss than semaglutide — and understanding why comes down to one key difference in how it works.

Tirzepatide is sold under two brand names: Mounjaro® (approved for type 2 diabetes) and Zepbound® (approved for chronic weight management and obstructive sleep apnea in patients with obesity). Both are manufactured by Eli Lilly, both contain the same molecule, and both are given as weekly subcutaneous injections.

For the broader context on all GLP-1 medications, start with our complete GLP-1 guide. For the direct comparison with semaglutide, see our head-to-head comparison article.

What Makes Tirzepatide Different: The Dual Agonist Mechanism

Most GLP-1 medications — including semaglutide (Ozempic, Wegovy) and liraglutide (Saxenda) — activate one hormone receptor: the GLP-1 receptor. Tirzepatide activates two: the GLP-1 receptor and the GIP receptor (glucose-dependent insulinotropic polypeptide).

GIP is another incretin hormone produced in your gut after eating. Like GLP-1, it helps regulate insulin release and blood sugar. But GIP also appears to play additional roles in fat metabolism and energy balance that GLP-1 alone doesn't fully address. When both receptors are activated simultaneously, the combined signal produces stronger effects on appetite suppression, blood sugar regulation, and metabolic function than either receptor alone.

Think of it this way: semaglutide turns down the volume on hunger through one channel. Tirzepatide turns it down through two channels at the same time. The result, demonstrated consistently across clinical trials, is greater average weight loss with the dual-agonist approach.

It's worth noting that the science of GIP in weight management is still evolving. The initial assumption was that blocking GIP might help with weight loss (since GIP promotes fat storage in some contexts), but tirzepatide's success with GIP agonism — activating the receptor rather than blocking it — revealed that the biology is more nuanced. The combination of GIP and GLP-1 activation appears to produce metabolic benefits that neither hormone achieves alone.

The Clinical Evidence: What the Trials Show

Tirzepatide's clinical trial program is called SURMOUNT, and the results have been consistently impressive.

SURMOUNT-1: In 2,539 adults with obesity or overweight (without diabetes), patients taking the highest dose of tirzepatide (15 mg) lost an average of 20.9% of their body weight over 72 weeks. More than one-third of participants lost over 25% of their body weight — a result that approaches what bariatric surgery achieves, but without surgery.

SURMOUNT-5 (head-to-head): This was the trial everyone was waiting for — a direct comparison of tirzepatide versus semaglutide in 751 adults with obesity but without diabetes. At 72 weeks, tirzepatide produced 20.2% average weight loss compared to 13.7% with semaglutide. About 78% of tirzepatide patients lost at least 15% of body weight, compared to 51% with semaglutide.

These aren't small differences. An additional 6-7 percentage points of body weight loss translates to meaningful clinical improvements in blood pressure, cholesterol, blood sugar, joint stress, sleep apnea severity, and overall quality of life.

Mounjaro vs. Zepbound: Same Drug, Different Labels

Just like the Ozempic/Wegovy situation with semaglutide, Mounjaro and Zepbound are the same molecule — tirzepatide — approved under different names for different conditions.

Mounjaro®: FDA-approved for type 2 diabetes management. Also approved for children aged 10 and older with type 2 diabetes. Insurance coverage is generally better for the diabetes indication.

Zepbound®: FDA-approved for chronic weight management in adults with obesity or overweight with at least one weight-related condition. Also uniquely approved for moderate to severe obstructive sleep apnea in adults with obesity — an indication that semaglutide doesn't currently have.

Both use the same prefilled injection pen format and the same dose escalation schedule.

Dosing Schedule: The Gradual Ramp-Up

Tirzepatide uses a structured dose titration to minimize gastrointestinal side effects:

Weeks 1-4: 2.5 mg weekly (starting dose — primarily for tolerability, not expected to produce significant weight loss)

Weeks 5-8: 5 mg weekly

Weeks 9-12: 7.5 mg weekly

Weeks 13-16: 10 mg weekly

Weeks 17+: 12.5 mg or 15 mg weekly (maximum dose, if needed and tolerated)

Not every patient needs or tolerates the maximum dose. Some achieve their weight loss goals at 10 mg, and the dose-response relationship means that each step up provides additional benefit but also potentially more side effects. Your prescriber will work with you to find the optimal dose that balances effectiveness with tolerability.

The titration schedule for tirzepatide is similar in duration to semaglutide's but starts at a higher absolute dose (2.5 mg vs. 0.25 mg). For a detailed comparison of how the two titration schedules differ, see our comparison article.

The Sleep Apnea Connection

One of Zepbound's unique features is its FDA approval for treating moderate to severe obstructive sleep apnea in adults with obesity. This makes it the first medication of its kind to receive this specific indication.

The connection is straightforward: excess weight, particularly around the neck and upper airway, is the primary driver of obstructive sleep apnea in most patients. Significant weight loss reduces airway compression, decreases the number of breathing interruptions during sleep, and can reduce or may help reduce the need for CPAP therapy in some patients.

Clinical trials showed that tirzepatide significantly reduced the apnea-hypopnea index (AHI) — the standard measure of sleep apnea severity — in patients with obesity. For patients who have both obesity and sleep apnea, tirzepatide addresses both conditions simultaneously, which simplifies treatment and improves overall health outcomes.

Cardiovascular Evidence: Where Does Tirzepatide Stand?

This is an important distinction from a cardiothoracic perspective. Semaglutide (Wegovy) has FDA-approved cardiovascular protection based on the SELECT trial. Tirzepatide doesn't yet have this specific FDA approval — the cardiovascular outcome trials for tirzepatide are still underway.

However, tirzepatide does produce greater weight loss, and substantial weight loss independently reduces cardiovascular risk factors including blood pressure, cholesterol, blood sugar, and systemic inflammation. The SUMMIT trial also showed that tirzepatide significantly improved outcomes in patients with heart failure with preserved ejection fraction (HFpEF) and obesity — a population that has historically been very difficult to treat.

For patients where cardiovascular risk reduction is the primary concern, the established evidence currently favors semaglutide. For patients where maximum weight loss is the priority, the evidence favors tirzepatide. For many patients, both goals matter, and the choice involves weighing the relative priorities. We discuss this in detail in our cardiovascular benefits article.

Side Effects: Similar but Not Identical

Tirzepatide's side effect profile is broadly similar to semaglutide's — primarily gastrointestinal effects including nausea, diarrhea, constipation, and vomiting. These are most common during dose escalation and generally improve over time.

At higher doses, tirzepatide may produce somewhat more GI side effects than semaglutide, consistent with its more powerful metabolic effects. In the SURMOUNT-5 head-to-head trial, discontinuation rates due to side effects were similar between the two medications, suggesting that the tolerability profile is comparable for most patients.

For the comprehensive side effect breakdown including management strategies and serious risk information, see our side effects guide.

Frequently Asked Questions

Is tirzepatide “better” than semaglutide?

Tirzepatide produces more weight loss on average. But “better” depends on your individual goals, health profile, insurance coverage, and how you respond to each medication. Semaglutide has stronger cardiovascular evidence. Tirzepatide has a sleep apnea indication. Neither is universally superior. See our comparison for the full analysis.

Is there a compounded version of tirzepatide?

Compounded tirzepatide has become available through some telehealth providers, typically at $299-399 per month. The same cautions that apply to compounded semaglutide apply here — it's not FDA-approved and quality can vary. Our compounded vs. brand-name article covers the broader compounding landscape.

Is there an oral tirzepatide option?

Not yet. Unlike semaglutide, tirzepatide is currently available only as a weekly injection. Eli Lilly is developing orforglipron, an oral non-peptide GLP-1 agonist, but it's a different molecule. See our oral GLP-1 guide for what's available now and what's coming.

Can I switch from semaglutide to tirzepatide?

Yes, with medical supervision. Your doctor will determine appropriate starting doses and monitor your response. Switching is most common when patients plateau on semaglutide or want to try tirzepatide's potentially greater weight loss effects.

This article will be updated as new clinical data and FDA actions become available. Last reviewed: April 3, 2026.

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before starting any new supplement or health program, especially if you have existing medical conditions or take prescription medications.

Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting any supplement, medication, or treatment program. Individual results may vary.